These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The in vivo characteristics of genetically engineered divalent and tetravalent single-chain antibody constructs. Wittel UA; Jain M; Goel A; Chauhan SC; Colcher D; Batra SK Nucl Med Biol; 2005 Feb; 32(2):157-64. PubMed ID: 15721761 [TBL] [Abstract][Full Text] [Related]
4. Cationization of monoclonal antibodies: another step towards the "magic bullet"? Vaisitti T; Deaglio S; Malavasi F J Biol Regul Homeost Agents; 2005; 19(3-4):105-12. PubMed ID: 16602624 [TBL] [Abstract][Full Text] [Related]
5. Engineered single chain antibody fragments for radioimmunotherapy. Huhalov A; Chester KA Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):279-88. PubMed ID: 15640791 [TBL] [Abstract][Full Text] [Related]
6. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients. Wong JY; Chu DZ; Yamauchi D; Odom-Maryon TL; Williams LE; Liu A; Esteban JM; Wu AM; Primus FJ; Beatty JD; Shively JE; Raubitschek AA J Nucl Med; 1998 Dec; 39(12):2097-104. PubMed ID: 9867150 [TBL] [Abstract][Full Text] [Related]
7. Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Baxter LT; Zhu H; Mackensen DG; Jain RK Cancer Res; 1994 Mar; 54(6):1517-28. PubMed ID: 8137258 [TBL] [Abstract][Full Text] [Related]
8. Tumor targeting properties of indium-111 labeled genetically engineered Fab' and F(ab')2 constructs of chimeric tumor necrosis treatment (chTNT)-3 antibody. Khawli LA; Alauddin MM; Hu P; Epstein AL Cancer Biother Radiopharm; 2003 Dec; 18(6):931-40. PubMed ID: 14969605 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and biodistribution of 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49. Chauhan SC; Jain M; Moore ED; Wittel UA; Li J; Gwilt PR; Colcher D; Batra SK Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):264-73. PubMed ID: 15791435 [TBL] [Abstract][Full Text] [Related]
10. Effects of genetic engineering on the pharmacokinetics of antibodies. Colcher D; Goel A; Pavlinkova G; Beresford G; Booth B; Batra SK Q J Nucl Med; 1999 Jun; 43(2):132-9. PubMed ID: 10429508 [TBL] [Abstract][Full Text] [Related]
11. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. Sundaresan G; Yazaki PJ; Shively JE; Finn RD; Larson SM; Raubitschek AA; Williams LE; Chatziioannou AF; Gambhir SS; Wu AM J Nucl Med; 2003 Dec; 44(12):1962-9. PubMed ID: 14660722 [TBL] [Abstract][Full Text] [Related]
12. Divalent forms of CC49 single-chain antibody constructs in Pichia pastoris: expression, purification, and characterization. Goel A; Beresford GW; Colcher D; Pavlinkova G; Booth BJ; Baranowska-Kortylewicz J; Batra SK J Biochem; 2000 May; 127(5):829-36. PubMed ID: 10788792 [TBL] [Abstract][Full Text] [Related]
13. Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design. Deyev SM; Lebedenko EN Bioessays; 2008 Sep; 30(9):904-18. PubMed ID: 18693269 [TBL] [Abstract][Full Text] [Related]
14. Targeting strategies for cancer radiotherapy. Buchsbaum DJ; Rogers BE; Khazaeli MB; Mayo MS; Milenic DE; Kashmiri SV; Anderson CJ; Chappell LL; Brechbiel MW; Curiel DT Clin Cancer Res; 1999 Oct; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342 [TBL] [Abstract][Full Text] [Related]
15. Penetratin improves tumor retention of single-chain antibodies: a novel step toward optimization of radioimmunotherapy of solid tumors. Jain M; Chauhan SC; Singh AP; Venkatraman G; Colcher D; Batra SK Cancer Res; 2005 Sep; 65(17):7840-6. PubMed ID: 16140953 [TBL] [Abstract][Full Text] [Related]
16. Possible consequences of human antibody responses on the biodistribution of fragments of human, humanized or chimeric monoclonal antibodies: a note of caution. Pimm MV Life Sci; 1994; 55(2):PL45-9. PubMed ID: 8015352 [TBL] [Abstract][Full Text] [Related]
17. Building and characterizing antibody-targeted lipidic nanotherapeutics. Kirpotin DB; Noble CO; Hayes ME; Huang Z; Kornaga T; Zhou Y; Nielsen UB; Marks JD; Drummond DC Methods Enzymol; 2012; 502():139-66. PubMed ID: 22208985 [TBL] [Abstract][Full Text] [Related]
18. Large scale production of recombinant antibodies by utilizing cellulose-binding domains. Benhar I; Berdichevsky Y Methods Mol Biol; 2003; 207():443-54. PubMed ID: 12412491 [No Abstract] [Full Text] [Related]
19. A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy. Schultz J; Lin Y; Sanderson J; Zuo Y; Stone D; Mallett R; Wilbert S; Axworthy D Cancer Res; 2000 Dec; 60(23):6663-9. PubMed ID: 11118050 [TBL] [Abstract][Full Text] [Related]
20. Biodistribution of 18F- and 125I-labeled anti-Tac disulfide-stabilized Fv fragments in nude mice with interleukin 2 alpha receptor-positive tumor xenografts. Choi CW; Lang L; Lee JT; Webber KO; Yoo TM; Chang HK; Le N; Jagoda E; Paik CH; Pastan I Cancer Res; 1995 Nov; 55(22):5323-9. PubMed ID: 7585595 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]